We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $440M
1-Year Est. Return 109.12%
This Fund
S&P 500
This Quarter Est. Return
+36.72%
1 Year Est. Return
+109.12%
3 Year Est. Return
+239.59%
5 Year Est. Return
+227.89%
10 Year Est. Return
+3,611.91%
AUM
$405M
AUM Growth
+$42.5M
Cap. Flow
-$59.3M
Cap. Flow %
-14.64%
Top 10 Hldgs %
57.09%
Holding
83
New
7
Increased
10
Reduced
24
Closed
8

Top Buys

Rank Stock Value
1
SLNO
Soleno Therapeutics
SLNO
+$3.93M
2
LRMR icon
Larimar Therapeutics
LRMR
+$2.46M
3
SPRY icon
ARS Pharmaceuticals
SPRY
+$2.02M
4
INSP icon
Inspire Medical Systems
INSP
+$1.74M
5
AQST icon
Aquestive Therapeutics
AQST
+$1.6M

Top Sells

Rank Stock Value
1
BPMC
Blueprint Medicines
BPMC
+$21.6M
2
MRUS
Merus
MRUS
+$11.6M
3
ASND icon
Ascendis Pharma A/S
ASND
+$7.37M
4
MLYS icon
Mineralys Therapeutics
MLYS
+$6.23M
5
URGN icon
UroGen Pharma
URGN
+$5.78M

Sector Composition

Rank Sector Weight
1 Healthcare 85.06%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BPMC
76
DELISTED
Blueprint Medicines
BPMC
– –
-168,763
Closed -$21.6M
GOSS icon
77
Gossamer Bio
GOSS
$87M
– –
-849,921
Closed -$1.05M
IFRX icon
78
InflaRx
IFRX
$271M
– –
-200,000
Closed -$158K
ITOS
79
DELISTED
iTeos Therapeutics
ITOS
– –
-140,847
Closed -$1.4M
PRCT icon
80
Procept Biorobotics
PRCT
$1.17B
– –
-3,000
Closed -$173K
YARW
81
Yarrow Bioscience, Inc. Common Stock
YARW
$111M
– –
-12,722
Closed -$1.05M
PVLA
82
Palvella Therapeutics
PVLA
$2.27B
– –
-43,348
Closed -$977K
1 2 3
4

Similar funds

CDMG
Creek Drive Management Group San Francisco, California $439M AUM
SCP
SailingStone Capital Partners Houston, Texas $440M AUM 127.21% 1-Year Est. Return
CAAM
Cape Ann Asset Management London, United Kingdom $440M AUM 96.23% 1-Year Est. Return
HCM
Harvey Capital Management Palm Beach, Florida $439M AUM 37.68% 1-Year Est. Return
BOA
Birnam Oak Advisors New York $441M AUM 37.12% 1-Year Est. Return
DBG
De Burlo Group Boston, Massachusetts $441M AUM 21.21% 1-Year Est. Return
SPT
Siemens Pension Trust Munich Germany, Germany $437M AUM 183.71% 1-Year Est. Return
BCM
Beck Capital Management Austin, Texas $437M AUM 59.35% 1-Year Est. Return

DAFNA Capital Management's Q3 2025 Portfolio in Review

As of Q3 2025, DAFNA Capital Management held 83 positions worth $405M, up 12% from $362M the previous quarter. Its ten largest holdings account for 57% of the portfolio.

DAFNA Capital Management withdrew a net $59.3M in Q3 2025, closing 8 positions and reducing 24 holdings. Its most notable exit was Blueprint Medicines, an estimated $21.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, down from 86% a quarter earlier.

Against the trend, DAFNA Capital Management opened a new position in Soleno Therapeutics worth $3.58M.

  • DAFNA Capital Management's largest Q3 2025 buy was Soleno Therapeutics: 53,000 shares worth $3.58M.
  • DAFNA Capital Management added most to Larimar Therapeutics in Q3 2025, an estimated $2.46M increase.
  • DAFNA Capital Management's biggest Q3 2025 reduction was Merus, cutting an estimated $11.6M.
  • DAFNA Capital Management fully exited Blueprint Medicines in Q3 2025, selling an estimated $21.6M.
  • DAFNA Capital Management's ten largest holdings make up 57% of its $405M portfolio in Q3 2025.
  • DAFNA Capital Management opened 7 new positions and closed 8 in Q3 2025.
  • DAFNA Capital Management's portfolio value rose 12% quarter-over-quarter to $405M.

Based on DAFNA Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.